Skip to main content

Table 1 Patients’ baseline data

From: Comparison of different laboratory tests in the evaluation of hemorrhagic risk of patients using rivaroxaban in the critical care setting: diagnostic accuracy study

Gender

n (%)

 Female

20 (50)

 Male

20 (50)

Rivaroxaban dosage

n (%)

 10 mg/day

12 (30.0)

 15 mg/day

19 (47.5)

 20 mg/day

9 (22.5)

Age

 

 Average (standard deviation)

69 (21)

 Minimum and maximum age

27–95